Enveda: $150 Million Series D Raised To Advance Clinical Trials And Enhance Leadership
By Amit Chowdhry ● Sep 11, 2025
Enveda, a clinical-stage biotechnology company focused on developing a new generation of small-molecule drugs sourced from nature, has announced a significant milestone with the close of its $150 million Series D funding round. The round was led by Premji Invest and included participation from a mix of new and existing investors such as Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners, FPV, Socium Ventures, Dimension, Level Ventures, Henry Kravis, IA Ventures, and Lux Capital. It follows a previous $150 million Series C round that included support from Sanofi. And this latest investment brings the company’s total funding to $517 million and marks its transition into unicorn status.